Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASLAN Keeps Eye On Maximizing Values After Fundraising

This article was originally published in PharmAsia News

Executive Summary

ASLAN has closed a Series C round involving some new investors that puts the Singapore venture in a more comfortable financial position and may allow it to complete pivotal trials for its lead oncology project. But its CEO says the main focus will continue to be on maximizing asset values.


Related Content

VC Roundup: 2Q Financings Fall As Per-Company Averages Rise


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts